中国药物评价Issue(4)：243-248,6.
曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述
Pharmacoeconomic Evaluation on Trastuzumab in Adjuvant Breast Cancer Therapy for HER2-Positive Breast Cancer:A Systematic Review
摘要
Abstract
Objective: To systematically evaluate the pharmacoeconomic vaule of Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer.Methods: A systematic literature search of cost-effectiveness studies on Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer published from 2003 to 2013 was carried out in PubMed, Science Direct, Springer Link and some other database.The studies were screened according to inclusion criteria and the systematic review was conducted according to Pharmacoeconomic methods.Results:The ICER of Trastuzumab in adjuvant breast cancer therapy for HER 2-positive breast cancer was$34307~126933/QALY in America, and C=35975~52753/QALY in Sweden, C=8148~162417/LYS in Norway and C=17000/LYG in Japan.Conclusion:Studies concerning the cost-effectiveness of traztuzumab for HER 2 positive breast cancer patients have not reached consistent conclusions.In the 15 literatures included , 4 of them concluded that Trastuzumab is not a cost-effective therapy with ICER a-bove the implemented willingness-to-pay thresholds.关键词
曲妥珠单抗/HER2阳性乳腺癌/药物经济学/综述Key words
Trastuzumab/HER2-positive breast cancer/Pharmacoeconomics/Review分类
医药卫生引用本文复制引用
刘永军,马林超..曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述[J].中国药物评价,2014,(4):243-248,6.
